Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation

American Journal of Transplantation

Volumn 13, Issue 7, 2013, Pages 1793-1805

  Bestard, O ^a,b   Lucia, M ^b   Crespo, E ^b   Van Liempt, B ^b,c   Palacio, D ^a,d   Melilli, E ^a   Torras, J ^a,b   Llaudo I ^b   Cerezo, G ^b   Taco, O ^a   Gil Vernet, S ^a   Grinyo J M ^a,b   Cruzado, J M ^a,b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Hospital Universitario San Vicente de Paul   (Colombia)

Author keywords

Cytomegalovirus infection; Elispot; kidney transplantation; T cell response

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; CYTOMEGALOVIRUS ANTIGEN IE 1; CYTOMEGALOVIRUS ANTIGEN PP65; GAMMA INTERFERON; GANCICLOVIR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; VALGANCICLOVIR; VIRUS ANTIGEN;

ADULT; ANTIGENICITY; ARTICLE; CELLULAR IMMUNITY; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURGICAL RISK;

ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; IMMEDIATE-EARLY PROTEINS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PROGNOSIS; RETROSPECTIVE STUDIES; T-LYMPHOCYTES;

EID: 84879550846     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12256     Document Type: Article

References (47)

1. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002; 2: 850.
2. Sagedal S, Hartmann A, Nordal KP, et al. Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival. Kidney Int 2004; 66: 329.
3. Hjelmesaeth J, Sagedal S, Hartmann A, et al. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia 2004; 47: 1550.
4. Hodson EM, Jones CA, Webster AC, et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid organ transplants: A systematic review of randomised controlled trials. Lancet 2005; 365: 2105.
5. Opelz G, Döhler B, Ruhenstroth A., Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 928.
6. Preiksaitis JK, Brennan DC, Fishman J, et al. Canadian Society of Transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005; 5: 218.
7. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: Results of a randomized clinical trial. Am J Transplant 2008; 8: 975.
8. Witzke O, Hauser I, Bartels M, et al. Valgancyclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-Year results of a randomized clinical trial. Transplant 2012; 93: 61-68.
9. Khoury JA, Storch GA, Bohl DL, et al. Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 2006; 6: 2134-2143.
10. Reischig T, Jindra P, Hes O, Svecová M, Klaboch J, Treska V., Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation. Am J Transplant 2008; 8: 69-77.
11. Singh N., Antiviral drugs for cytomegalovirus in transplant recipients: Advantages of preemptive therapy. Rev Med Virol 2006; 16: 281-287, review.
12. Grundy JE, Lui SF, Super M, et al. Symptomatic cytomegalovirus infection in seropositive kidney recipients: Reinfection with donor virus rather than reactivation of recipient virus. Lancet 1988; 2: 132-135.
13. Paya CV, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
14. Einsele H, Ehninger G, Hebart H, et al. Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation. Blood 1995; 86: 2815-2820.
15. Mattes FM, Hainsworth EG, Geretti AM, et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 2004; 189: 1355-1361.
16. Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T cell clones from the donor. N Engl J Med 1995; 333: 1038-1044.
17. Sacre K, Carcelain G, Cassoux N, et al. Repertoire, diversity, and differentiation of specific CD8 T cells are associated with immune protection against human cytomegalovirus disease. J Exp Med 2005; 201: 1999-2010.
18. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ cells dominate the memory compartments of exposed subjects. J Exp Med 2005; 202: 673-685.
19. Pahl-Seibert MF, Juelch M, Podlech J, et al. Highly protective in vivo function of cytomegalovirus IE-1 epitope-specific memory CD8 T cells purified by T cell receptor-based cell sorting. J Virol 2005; 79: 5400-5413.
20. Reddehase MJ., Antigens and immunoevasins: Opponents in cytomegalovirus immune surveillance. Nat Rev Immunol 2002; 2: 831-844.
21. Bunde T, Kirschner A, Hoffmeister B, et al. Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells. J Exp Med 2005; 201: 1031-1036.
22. Radha RS, Jordan D, Puliyanda S, et al. Cellular immune responses to cytomegalovirus in renal transplant recipients. Am J Transplant 2005; 5: 110-117.
23. Shlobin OA, West EE, Lechtzin N, et al. Persistent cytomegalovirus- specific memory responses in the lung allograft and blood following primary infection in lung transplant recipients. J Immunol 2006; 176: 2625-2634.
24. Mattes FM, Vargas A, Kopycinski J, et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant 2008; 8: 990-999.
25. Kumar D, Chernenko S, Moussa G, et al. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant 2009; 9: 1214-1222.
26. Gratama JW, van Esser JW, Lamers CH, et al. Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection. Blood 2001; 98: 1358-1364.
27. Gandhi MK, Khanna R., Human cytomegalovirus: Clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4: 725-738.
28. Humar A, Mazzulli T, Moussa G, et al. Valganciclovir Solid Organ Transplant Study Group. Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients. Am J Transplant 2005; 5: 1065-1070.
29. Sester M, Sester U, Gartner B, et al. Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 2001; 71: 1287-1294.
30. Sester M, Sester U, Gärtner BC, Girndt M, Meyerhans A, Köhler H., Dominance of virus-specific CD8 T cells in human primary cytomegalovirus infection. J Am Soc Nephrol 2002; 13: 2577-2584.
31. Westall GP, Mifsud NA, Kotsimbos T., Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T cell immunity. Am J Transplant 2008; 8: 1749-1754.
32. Gerna G, Lilleri D, Chiesa A, et al. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am J Transplant 2011; 11: 2463-2714.
33. Nickel P, Bold G, Presber F, et al. High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transpl Immunol 2009 20: 238-242.
34. Manley TJ, Luy L, Jones T, et al. Immune evasion proteins of human cytomegalovirus do not prevent a diverse CD8+ cytotoxic T cell response in natural infection. Blood 2004; 104: 1075-1082.
35. Elkington RS, Walker T, Crough M, et al. Ex vivo profiling of CD8+-T cell responses to human cytomegalovirus reveals broad and multispecific reactivities in healthy virus carriers. J Virol 2003; 77: 5226-5240.
36. Wills MR, Carmichael AJ, Weekes MP, et al. Human virus-specific CD8+ CTL clones revert from CD45ROhigh to CD45RAhigh in vivo: CD45RAhighCD8+ T cells comprise both naive and memory cells. J Immunol 1999; 162: 7080-7087.
37. Stinski MF., Sequence of protein synthesis in cells infected by human cytomegalovirus: Early and late virus-induced polypeptides. J Virol 1978; 26: 686-701.
38. Rice GP, Schrier RD, Oldstone MB., Cytomegalovirus infects human lymphocytes and monocytes: Virus expression is restricted to immediate-early gene products. Proc Natl Acad Sci USA 1984; 81: 6134-6138.
39. Waldman WJ, Knight DA, Huang EH, Sedmak DD., Bidirectional transmission of infectious cytomegalovirus between monocytes and vascular endothelial cells: An in vitro model. J Infect Dis 1995; 171: 263-272.
40. Crough T, Fazou C, Weiss J, et al. Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8(+) T cell response. Virology 2007; 81: 11538-11542.
41. La Rosa C, Limaye AP, Krishnan A, Longmate J, Diamond DJ., Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 2007; 195: 633-644.
42. Zhang W, Caspell R, Karulin AY, et al. ELISPOT assays provide reproducible results among different laboratories for T cell immune monitoring even in hands of ELISPOT-inexperienced investigators. J Immunotoxicol 2009; 6: 227-234.
43. Janetzki S, Panageas KS, Ben-Porat L, et al. Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Cancer Immunol Immunother 2008; 57: 303-315.
44. Janetzki S, Britten CM., The impact of harmonization on ELISPOT assay performance. Methods Mol Biol 2012; 792: 25-36.
45. Weinberg A, Hodges TN, Li S, Cai G, Zamora MR., Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J Clin Microbiol 2000; 38: 768-772.
46. Reischig T, Hribova P, Jindra P, et al. Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation. J Am Soc Nephrol 2012; 23: 1588-1597.
47. Humar A, Lebranchu Y, Vincenti F, et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010; 10: 1228-1237.